Lanfan Medical: Announcement on the transaction progress of the transfer of 100% equity of Wuhan Bikel Rescue Supplies Co., Ltd. and the resignation of the vice president
Securities code: 002382 Securities abbreviation: Lanfan Medical Announcement number: 2026-066
Blue Sail Medical Co., Ltd.
Regarding the transfer of 100% equity of Wuhan Bikel Rescue Supplies Co., Ltd.
Transaction Progress and Announcement of the Vice President’s Resignation
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Transaction Overview
In order to further focus on the core business, increase cash reserves, revitalize existing assets, and shorten the management radius, Blue Sail Medical Co., Ltd. (hereinafter referred to as the "Company" or "Lan Sail Medical") on June 29, 2026 The 43rd meeting of the sixth session of the Board of Directors was held on the same day, and the "Proposal on the Transfer of 100% Equity Interest in Wuhan Bikel Rescue Supplies Co., Ltd." was reviewed and approved, and the company agreed to transfer 100% of the equity held by the company in Wuhan Bikel Rescue Supplies Co., Ltd. (hereinafter referred to as "Wuhan Bikel") to Wuhan Mingde Biotechnology Co., Ltd. (stock code 002932.SZ, hereinafter referred to as "Mingde Biotechnology"), with a transfer price of RMB 19,000 Ten thousand yuan, the price of this transaction is based on the appraisal value determined by Zhonglianhu Pingzi (2026) No. 58 "Asset Appraisal Report" and is determined through negotiation between the parties to the transaction. After the completion of this transaction, the company will no longer hold the equity of Wuhan Bikel, and Wuhan Bikel will no longer be included in the company's consolidated statements.
The company's initial investment in acquiring 100% equity of Wuhan Bikel in 2020 was 286 million yuan. Wuhan Bikel contributed profits to the company and distributed a total dividend of 200 million yuan to the company. The consideration for this equity transfer was 190 million yuan. Taking into account Wuhan Bikel's profits during the company's holding period, the dividends the company has received from Wuhan Bikel, and the pricing of the transfer of Wuhan Bikel's equity, it is expected that the company's transfer of 100% of Wuhan Bikel's equity will not result in investment losses. The company will conduct accounting treatment for this transaction in accordance with the "Accounting Standards for Business Enterprises" and other relevant regulations. The final impact data on the company's performance shall be based on the company's annual audited financial report data.
According to relevant regulations such as the Stock Listing Rules of the Shenzhen Stock Exchange and the Articles of Association of Lansail Medical Co., Ltd. (hereinafter referred to as the "Articles of Association"), this equity transfer matter is within the decision-making authority of the board of directors and does not need to be submitted to the company's shareholders' meeting for review. For details, please refer to the "Announcement on the Proposed Transfer of 100% Equity Interest in Wuhan Bikel Rescue Supplies Co., Ltd." disclosed by the company on the cninfo.com on June 30, 2026 (announcement number: 2026-064).
2. Transaction progress
As of the disclosure date of this announcement, Mingde Biotech has paid in full the equity transfer amount of RMB 190 million in strict accordance with the "Agreement on Cash Payment for Asset Purchase", and Wuhan Bikell has completed the industrial and commercial change registration procedures. The specific situation is as follows:
Change matters Before change After change
Limited liability company (foreign-invested enterprise) Limited liability company (natural person investment or holding enterprise type
Sole proprietorship of a legal person)
Legal Representative Liu Wenjing Zhang Yongchen
Shareholders Lanfan Medical Co., Ltd. Wuhan Mingde Biotechnology Co., Ltd. Liu Wenjing (Chairman)
Zhang Yongchen (Chairman, General Manager) Zhang Yongchen (Manager, Director)
Liu Yi (Director)
Main Personnel Liu Shanshan (Financial Manager)
Li Chaohui (Director, Chief Financial Officer) Shi Wensheng (Director)
Han Qian (Supervisor)
Bai Xuelian (Supervisor)
Note: Except for changes in the above industrial and commercial registration information, other matters remain unchanged.
After the completion of this transaction, the company will no longer hold any equity in Wuhan Bikel, and Wuhan Bikel and its subsidiaries will no longer be included in the company's consolidated financial statements from the date of completion of the transaction.
3. Resignation of Vice President
The company's board of directors recently received a written resignation report submitted by Vice President Mr. Zhang Yongchen. Since the company has completed the transfer and delivery of 100% of the equity of Wuhan Bikel, Wuhan Bikel is no longer affiliated with the company. Taking into account the overall adjustment arrangements for the equity structure and management structure brought about by this equity transfer, Mr. Zhang Yongchen has applied to resign from the position of vice president of the company. After resigning, he will hold a full-time management position in Wuhan Bikel and be responsible for the business development of it and its subsidiaries. The original expiration date of Mr. Zhang Yongchen’s position as Vice President is the expiration date of the sixth term of the Company’s Board of Directors.
In accordance with the relevant provisions of the "Company Law of the People's Republic of China", the Stock Listing Rules of the Shenzhen Stock Exchange and the "Articles of Association", Mr. Zhang Yongchen's resignation report will take effect from the date it is delivered to the company's board of directors, and he will no longer hold any position in the company after his resignation. Mr. Zhang Yongchen has completed the handover of work related to the position of vice president in accordance with the company's "Resignation Management System for Directors and Senior Management Personnel", and his resignation will not affect the company's normal production and operation activities.
As of the disclosure date of this announcement, Mr. Zhang Yongchen holds 45,350 shares of the company, accounting for 0.0045% of the company's total share capital. There are no commitments that should be fulfilled but have not been fulfilled. After his resignation, he did not violate the relevant non-competition agreement in Wuhan Bikel. The shares held will be managed in strict accordance with the "Company Law of the People's Republic of China", "Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies" and other relevant regulations.
Mr. Zhang Yongchen has performed his duties diligently and diligently during his tenure, and has made positive contributions to the development of the company's emergency rescue business segment and the smooth advancement of this equity transfer. The company's board of directors expresses its sincere gratitude to him.
4. Risk warning
Wuhan Bikel may face uncertain factors such as macroeconomics, international environment, market competition, and industry policy changes in its future operations and management. There is a possibility that the company may need to carry out performance commitment compensation and asset impairment test compensation. Investors are advised to pay attention to investment risks.
The company will perform its information disclosure obligations in a timely manner in accordance with the requirements of relevant laws, regulations, normative documents and the progress of the transaction.
5. Documents for reference
"Business License of Wuhan Bikel Rescue Supplies Co., Ltd.";
"Resignation Report" submitted by Mr. Zhang Yongchen.
Announcement is hereby made.
Board of Directors of Lanfan Medical Co., Ltd.
August 18, 2026